skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study

Moffa, Simona ; Mezza, Teresa ; Ferraro, Pietro Manuel ; Di Giuseppe, Gianfranco ; Cefalo, Chiara M A ; Cinti, Francesca ; Impronta, Flavia ; Capece, Umberto ; Ciccarelli, Gea ; Mari, Andrea ; Pontecorvi, Alfredo ; Giaccari, Andrea

Frontiers in endocrinology (Lausanne), 2023-05, Vol.14, p.1124116-1124116 [Periódico revisado por pares]

Switzerland: Frontiers Media S.A

Texto completo disponível

Citações Citado por
  • Título:
    Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study
  • Autor: Moffa, Simona ; Mezza, Teresa ; Ferraro, Pietro Manuel ; Di Giuseppe, Gianfranco ; Cefalo, Chiara M A ; Cinti, Francesca ; Impronta, Flavia ; Capece, Umberto ; Ciccarelli, Gea ; Mari, Andrea ; Pontecorvi, Alfredo ; Giaccari, Andrea
  • Assuntos: Animals ; Blood Glucose - metabolism ; BMI ; C-Peptide ; diabetes ; Endocrinology ; Glucose ; Glucose Tolerance Test ; Humans ; Insulin - metabolism ; Mice ; PCSK 9 inhibition ; Pilot Projects ; precision medicine ; statins ; β-cell
  • É parte de: Frontiers in endocrinology (Lausanne), 2023-05, Vol.14, p.1124116-1124116
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Reviewed by: Aldo Bonaventura, ASST Sette Laghi, Italy; Peter Mikael Nilsson, Lund University, Sweden
    Edited by: Lu Cai, University of Louisville, United States
  • Descrição: Anti-PCSK9 monoclonal antibodies are effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. PCSK9, however, is also expressed in tissues, including the pancreas, and studies on PCSK9 KO mice have shown impaired insulin secretion. Statin treatment is already known to affect insulin secretion. Our aim was to conduct a pilot study to evaluate the effect of anti-PCSK9 mAb on glucose metabolism and β-cell function in humans. Fifteen non-diabetic subjects, candidates for anti-PCSK9 mAb therapy, were enrolled. All underwent OGTT at baseline and after 6 months of therapy. During OGTT, insulin secretion parameters were derived from C-peptide by deconvolution (β cell glucose sensitivity). Surrogate insulin sensitivity indices were also obtained from OGTT (Matsuda). Glucose levels during OGTT were unchanged after 6 months of anti-PCSK9 mAb treatment, as well as insulin and C-peptide levels. The Matsuda index remained unchanged, while β-cell glucose sensitivity improved post-therapy (before: 85.3 ± 65.4; after: 118.6 ± 70.9 pmol min m mM ; p<0.05). Using linear regression, we found a significant correlation between βCGS changes and BMI (p=0.004). Thus, we compared subjects with values above and below the median (27.6 kg/m ) and found that those with higher BMI had a greater increase in βCGS after therapy (before: 85.37 ± 24.73; after: 118.62 ± 26.83 pmol min m mM ; p=0.007). There was also a significant correlation between βCGS change and Matsuda index through linear regression (p=0.04), so we analyzed subjects who had values above and below the median (3.8). This subgroup analysis showed a slight though not significant improvement in βCGS in more insulin resistant patients, (before: 131.4 ± 69.8; after: 170.8 ± 92.7 pmol min m mM ; p=0.066). Our pilot study demonstrates that six-month treatment with anti-PCSK9 mAb improves β-cell function, and does not alter glucose tolerance. This improvement is more evident in patients with greater insulin-resistance (low Matsuda) and higher BMI.
  • Editor: Switzerland: Frontiers Media S.A
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  13 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.